The use of antisense oligonucleotides as tools for modulating gene expression represents a novel strategy for designing drugs to treat a variety of diseases. Several factors, including cellular uptake and internalization of the oligonucleotides, are important parameters in determining the effectiveness of antisense agents such as therapeutic drugs. We have studied oligonucleotides uptake in normal and leukemic human hematopoietic cells, such as peripheral blood, bone marrow (BM), and HL-60 cell line; and have found that, in normal human blood and BM, myeloid cells and B cells preferably took up more oligonucleotides than T cells. There NTISENSE oligonucleotides are short sequences of DNA that form specific hydrogen bonds with complementary single-stranded mRNA sequences or with doublestranded DNA, allowing regulation of specific viral or cellular gene expression. They are widely used as research tools for inhibiting specific gene expression, and are under investigation for possible use as therapeutic agents.' Several human clinical trials are ongoing for viral infections and leukemias.2.6 Nevertheless, insufficient cellular uptake of oligonucleotide and lack of a precise understanding of how and where antisense oligonucleotides perturb gene expression impose limits on the therapeutic and experimental usefulness of these compounds. From the studies published to date describing cellular uptake of oligonucleotides, it seems that oligonucleotide uptake generally is saturable, sequence independent, and temperature and energy d e~e n d e n t .~ Although there is some evidence to suggest that there are cellular surface receptors for oligonucleotides uptake, these have not been further characterized or Recent studies show that oligonucleotide uptake occurs primarily through concentration dependent endocytosis mediated by a receptor-like mechanism at low concentration (< 1 pmol/L) with fluid phase endocytosis becomes more prominent above this concentration." Oligonucleotide uptake is heterogeneous in different subsets of primary murine lymphocytes and inducible upon stimulation with mitogens.""3
was no marked difference in oligonucleotide uptake between CD4+ helper T cells and CD8+ cytolytic T cells. Leukemic cells had greater oligonucleotide uptake than their normal counterparts. Furthermore, oligonucleotide uptake was closely related to cell activation status and can be modulated by growth factors or inhibitors. These studies provide a basis for using oligonucleotides as therapeutic drugs both in vitro and in vivo. This is a US government work. There are no restrictions on its use.
been achieved during the last two decades in the treatment of leukemias, obtaining cures still remains problematic. However, in the past few years, increasing understanding of the processes regulating cell growth, differentiation and malignant transformation, and the development of novel therapeutics have led to new opportunities for the treatment of leukemias." Abnormal activation of proto-oncogenes perturbs cell proliferation and differentiation, and is a major event in the pathogenesis of leukemias." Using antisense oligonucleotides to downregulate overexpressed oncogenes represents a novel approach for the treatment of leukealone or in combination with other antileukemic therapies, in ex vivo bone marrow (BM) purging, or in vivo treatments. Several antisense oligonucleotide approaches have been actively pursued in preclinical experiments and human trials in leukemia Investigation of oligonucleotide uptake and delivery in normal versus malignant human hematopoietic tissues may provide useful information for further development of new therapeutic approaches.
In the work presented here, we studied oligonucleotide uptake in normal and leukemic human leukocytes and the association of oligonucleotide uptake with cell activation states. The studies were performed using fluorescent-labeled phosphorothioate oligodeoxynucleotides in human peripheral blood (PB), BM cells, and a human promyelocytic leukemia cell line. mias,'".'7 Antisense oligonucleotides may be able to be used
MATERIALS AND METHODS

Synthesis of oligonucleotides.
Phosphorothioate oligodeoxynucleotide (PS-oligonucleotide) was synthesized on an automated synthesizer (Applied Biosystems, 380B, Foster City, CA) using phosphoramidite chemistry.'y To synthesize fluorescent isothiocyanate (F1TC)-labeled oligonucleotide, the last coupling step was performed using fluorescein-labeled amidite (Pharmacia, Piscataway, NJ)."' The oligonucleotides were deprotected by treatment with concentrated ammonium hydroxide at 55*C for I2 hours and were purified by polyacrylamide gel electrophoresis, desalted, and lyophilized to dryness before use. Oligonucleotides were synthesized with three different sequences (Oligo 1 : 5'-GAG AAC GCT GGA CCT TCC AT-3', Oligo 2: 5'-TGC TAG CTG TGC CTG TAC CT-3' and Oligo 3: 5'-CTC TCG CAC CCA TCT CTC TCC P C T-3'). Because there was no apparent difference in cellular uptake in initial experiments, these three sequences were used interchangeably in subsequent experiments. In the slot-blot experiment, a phosphodiester oligonucleotide (Oligo 4) Leukemic patients were studied before receiving treatment or during relapse. The cells were purified by passing through Histopaque (Sigma. St Louis, MO) to remove red blood cells, granuocytes. and debris. The cells were then washed. and cultured at 10" cellslmL in RPMI complete media [RPMI-1640 media supplemented with 10% heat inactivated (56% for 30 minutes) fetal bovine serum, 100 U/ mL penicillin, I 0 0 pg/mL streptomycin, 2 mmol/L L-glutamine, and 50 pmol/L 2-mercaptoethanolI. In some experiments, growth factors interleukin-3 (IL-3) (25 ng/mL) and Stem Cell Factor ([SCF]. 50 ng/mL) were included in the culture. Cells that had been cultured for longer than 4 hours were repurified over Histopaque (Sigma) to eliminate dead cells and debris before further studies.
Human promyelocytic leukemia cell line HL-60 (American Type Culture Collection, [ATCC], Rockville. MD) were also used in this study. The cells were cultured under the same condition as human primary cells, except in some experiments, all-trons-retinoic acid ([ATRA], Sigma) (concentration ranging from 10" to 10" mol/L) was included in the culture to inhibit cell growth.
Oligorlttcleotirle ttptctke srurlics. Oligonucleotide uptake experiments were set up by culturing cells The samples were loaded on a nylon membrane and the membrane was first prehybridized in 5 mL of hybridization buffer ( I mol/L NaCI, l % SDS. IO% dextran sulfate, 1 0 0 pg/mL ssDNA) for 2 hours at 37°C and then hybridized overnight with '*P-labeled Oligo 4, which sequence is complementary to that of Oligo 3. The membrane was washed twice with 6 X saline sodium citrate (SSC), exposed for autoradiography and phosphoimaging. The mean concentrations of the samples were plotted against known concentrations of the oligonucleotides. The experiments were done in triplicate.
(2) Fluorescent-labeled oligonucleotide uptake: HL-60 cells (2 X 10' cellsltube. in a volume of 200 pL RPM1 complete media) were incubated with 2 pg of fluorescent-labeled oligonucleotide (Oligo 3) (final concentration 0.8 pmollL) at either 37'C. or 4°C. At 0.5, I, 2. 4. 8, and 24 hours of incubation, cells were washed twice with PBS buffer and resuspended in FACS buffer supplemented with propidium iodide ( I O pg/mL) to allow discrimination of dead cells from viable cells. Flow cytometric data on 5,000 cells were acquired in histograms on a Epics XL. Data were analyzed using Epics XL, version I .5 software after gating on viable cells. The mean fluorescence intensities from the histograms were calculated. Experiments were done in duplicate.
Cell proliferation studies. HL-60 cells (5 X 10' cellslml) were plated in 96-well dishes in a final volume of 1 0 0 pL. All-trans- retinoic acid was added to the cells at concentrations ranging from IO"' to IO-' mol/L. After 72 hours in culture, cells were pulsedlabeled with 0.5 pCi 'H-thymidinel well (in 20 pL of RPM1 media) for 4 hours. Cells were then harvested by automatic cell harvester (Skatron, Sterling, VA) and filters counted by a scintillation counter. The experiments were done in triplicate.
RESULTS
The interpretation of experiments using antisense oligonucleotides in vivo in animals or humans is critically dependent on whether cell uptake is homogenous or heterogeneous. The therapeutic efficacy of antisense oligonucleotides would be improved if they were preferentially taken up by the target cells of interest. With this in mind, the present study was performed to study the level of oligonucleotide uptake among different lineages of human PB and BM cells.
Oligonucleotide uptake in normal humctn cells. To study oligonucleotide uptake in BM cells, fresh normal human BM were procured and set to culture with fluorescent-labeled oligonucleotide at 37'C for4 hours, stained with fluorochome conjugated MoAbs (CD20', CD7'. and CDIS' antibodies) at 4'C for 20 minutes, and analyzed by flow cytometry as described in Materials and Methods. Our earlier study showed that under this condition, the fluorescent labeled oligonucleotide was mainly present intracellularly, with predominant cytoplasmic staining and very little nuclear or cell surface staining. In addition, there was no significant degradation of the phosphorothioate oligonucleotide or free fluorescent dye detected at this time point." Figure I A and CD33' antibodies). As shown in Fig 2, oligonucleotide uptake was generally low in fresh normal human PB, both in T (CD4' and CD8' cells) and B (CD229 cells. There were no marked differences in the level of oligonucleotide uptake between CD4' helper T cells and CD8' cytolytic T cells. Myeloid (CD33+) cells had higher levels of oligonucleotide uptake than T or B cells, similar to what was observed in normal human BM cells.
Validating Jluorescent oligonucleotide uptake studies.
To confirm that the flow cytometry was measuring intracellular oligonucleotides rather than surface-bound; and to determine whether the method was quantitative and consistent over time, we performed oligonucleotide uptake studies with both fluorescent oligonucleotide followed by detection with flow cytometry and also with unlabeled oligonucleotide fol- lowed by detection with slot-blot and compared the results. At various time points over a 24 hour period, cells were washed extensively to remove most of the surface-bound oligonucleotides, and intracellular oligonucleotides were then extracted and quantitated by slot blot. Figure 3 shows the autoradiography and standard curve of the oligonucleotide with the known concentrations. It shows that the slotblot is a quantitative and sensitive procedure for detection of oligonucleotide, as demonstrated earlier." The mean densities of each samples were then plotted against known concentrations of the oligonucleotide. The time course study with slot-blot showed that intracellular oligonucleotide uptake was time-dependent (Fig 4A) . Cells took up oligonucleotide at a more rapid pace during the first 4 hours and reached plateau at around 8 to 12 hours. A time course study of cellular accumulation of oligonucleotide by flow cytometry (incubation at 37°C) showed similar profiles to those observed with the cell extraction techniques (Fig 4B) . Membrane binding is a minor fraction of the total cell-associated oligonucleotide because cells incubated at 4% had only a small quantity of staining. We did not pursue the oligonucleotide cellular surface binding studies with slot-blot approach: because incubating cells at 4'C at extended time will result in cell viability change which is undetectable by slot-blot, therefore causing artifacts.".22 These data indicate flow cytometry can be used to measure intracellular accumulated oligonucleotides, and it is quantitative and consistent over a time course of at least 24 hours.
Mean Density
Oligonucleotide uptake in leukemic human cells. termine whether oligonucleotide uptake in leukemic cells may differ from their normal counterparts, we studied oligonucleotide uptake in PB samples from patients with ALL or AML. These leukemias had been phenotyped as CD7+ and CD13+, respectively. In each patient, the great majority of phenotype positive cells appeared to be malignant. This made it possible to compare their general level of oligonucleotide uptake with that of the residual normal cells (CD7-or CD13-, respectively) within the same patients (Fig 5) . The level of oligonucleotide association with the phenotype positive leukemic cells was far higher than that of nonleukemic phenotype positive cells (compare to CD7' normal cells in Fig 1, and CD13 ' normal cells in Fig 5C) . Of note, this comparison also shows that for phenotype negative cells, oligonucleotide uptake in the leukemic patients was similar to that of normal controls (Fig 5C) .
Modulating oligonucleotide uptake. To address the question whether oligonucleotide uptake can be improved by inducing cell activation, we stimulated the BM cells by culture in the presence of the hematopoietic growth factors, IL-3 (25 ng/mL) and SCF (50 ng/nL), or in the absence of any additional growth factors for 48 hours before regular oligonucleotide uptake studies were performed. In BM cells from AML patients, CD34' cells (a major population in AML BM) had higher oligonucleotide uptake compared with CD34-cells (a minor population in AML BM). When stimulated with growth factors, the oligonucleotide uptake of CD34+ was further increased (Fig 6C) . A slightly less dramatic increase in oligonucleotide uptake was seen in ALL cells cultured with IL-3 and SCF (Fig 6E) . In unstimulated normal human BM cells, relatively few CD34' cells had a high level of oligonucleotide uptake. However, when stimulated with IL-3 and SCF, far more CD34+ cells had high levels of oligonucleotide uptake (not shown).
By the same token, when cell growth was inhibited, there was a decrease in oligonucleotide uptake. HL-60 cells, which derive from human promyelocytic leukemia, had a high level of cell proliferation. When cultured with all-trans-retinoid acid, a vitamin A derivative that has profound antitumor effects by inhibiting cell proliferation and inducing cell differentiati~n?~ the cell proliferation rate decreased, as measured by 'H-thymidine incorporation (Fig 7) . ATRA treated cells also showed concentration-dependent decreased oligonucleotide uptake compared with untreated cells (Fig 8) . These results confirm that oligonucleotide uptake is closely related to cell activation status.
DISCUSSION
Antisense oligonucleotides are short sequences of DNA that form specific hydrogen bonds with complementary target mRNA sequences allowing modulation of specific foreign or cellular gene expression. They are widely used as research tools for inhibiting gene expression and are under investigation for possible use as therapeutic agents. The potential utility of antisense oligonucleotide therapy for treatment of viral infections and selected cancers will ultimately 
'
Concentration of ATRA (log M) B cells took up more oligonucleotide than T cells, confirming earlier studies in murine lymphocytes.'"" Myeloid/macrophages took up more oligonucleotide compared with B cells or T cells. Neutrophils had a very low level of oligonucleotide uptake. Oligonucleotide intracellular localization and trafficking may differ among different cell populations. Indeed, it has been reported that in HL-60 human promyelocytic leukemia cells, oligonucleotide appeared to localize in endosomes, in which they are acidified and undergo efflux relatively slowly'4; but in K562 human chronic leukemia cells, once internalized, oligonucleotides move from the endosomal compartment into the cytoplasm and thence into the nucleus."' In future studies, it would be interesting to pursue further the fate of oligonucleotide in myeloid/macrophages, which are the major cells that take up the oligonucleotide in normal human hematopoietic tissues. T cells had a generally low level of oligonucleotide uptake, and no significant difference in uptake was observed between CD4' and CD8' cells. Human leukemic cells took up more oligonucleotide compared with normal or residual cells in the same patient. This fact may provide an therapeutic advantage for using antisense oligonucleotide in leukemia patients. This increased oligonucleotide uptake in leukemic cells may explain why, at doses which failed to inhibit the growth of normal human hematopoietic, c-myb antisense oligonucleotide was able to inhibit the growth of malignant hematopoietic progenitors.25 The reason why leukemic cells take up more oligonucleotide than normal cells is unclear, but it may be caused by the fact that leukemic cells are more actively dividing cells than normal cells. As shown in the present report, oligonucleotide uptake is closely related to the cell ZHAO ET AL cycle in that activated cells take up more oligonucleotide compared with nonactive cells. Our earlier studies of oligonucleotide uptake with murine BM cells, showed that oligonucleotide uptake was stage specific during B-cell differentiation.'6 A relatively low level of oligonucleotide uptake was observed among pre-Pro-and early Pro-B cells. Late Pro-B-and pre-B cells had increased oligonucleotide uptake, whereas mature B cells had a low level of oligonucleotide uptake. Because cell activation status may vary during cell maturation, the differences we observed in oligonucleotide uptake during murine BM B-cell maturation may also be caused by their different activation status. Because there is evidence that there may be receptors or DNA-binding proteins that are responsible for oligonucleotide uptake:." activated cells may have increased expression of receptor(s) or DNA-binding protein(s) resulting in increased oligonucleotides uptake.
Hematopoietic growth factors, such as G-CSF and GM-CSF, have been used clinically to sensitize leukemic cells before cytostatic treatment or to enhance recovery of normal hematopoiesis after intensive chemotherapy." Because oligonucleotides uptake can be improved by inducing cell activation, further investigation into the combination of human antisense oligonucleotide therapy with growth factors immune therapy in certain leukemias would be of interest.
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